Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

But toxicity will be closely watched in future trials.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.

The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

And first data with a low dose are particularly unimpressive.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.